Taeguk Pharmciclovir Tablet (Pharmaciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer 250 mg of famciclovir orally per dose 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of initial genital herpes infection Adults: Administer 250 mg of this medicine orally per dose 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes infection Adults: Administer 125 mg of this medicine orally per dose 2 times daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer 250 mg of this medicine orally per dose 2 times daily. Periodically discontinue treatment every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Since the clearance of this medicine is reduced in patients with renal impairment, dose adjustment should be undertaken with care. The dosage and administration for these patients are as follows. 1) Treatment of herpes zoster and initial genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose 2 times daily 10～29 250 mg per dose once daily 2) Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 125 mg per dose 2 times daily 10～29 125 mg per dose once daily 3) Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose 2 times daily 10～29 125 mg per dose 2 times daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients undergoing hemodialysis, administration every 48 hours, taking the dialysis interval into account, is preferable. Since 4 hours of hemodialysis reduces the plasma concentration of this medicine by approximately 75%, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is necessary for patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, no definite recommended dose has been established.

This medication should not be administered to certain patients. It must not be used by patients who have had an allergic reaction to this medication, its components, or the active ingredient, penciclovir. Furthermore, as this medication contains lactose, patients with genetic disorders that prevent them from digesting lactose should not take it. Patients with poor kidney function should use this medication with caution and may need dosage adjustments. Mild side effects such as headaches or nausea may occur while taking this medication, but they are usually not severe. Occasionally, blood-related side effects such as thrombocytopenia or leukopenia may occur, so caution is advised. Symptoms such as mental dizziness, drowsiness, confusion, and hallucinations may appear, especially in older patients. Symptoms of rapid heartbeat or gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea are also commonly reported. Liver function test results may change, and jaundice may rarely appear. Skin reactions such as rashes, itching, urticaria, and swelling around the face or eyes may also occur. In patients with poor kidney function, acute renal failure has been rarely reported, so kidney status should be closely monitored. This medication does not cure genital herpes, and it is important to avoid sexual contact and maintain safe sexual practices even during treatment. If symptoms such as dizziness, drowsiness, or confusion appear while taking this medication, it is advisable to refrain from driving or operating machinery. Patients with slight liver impairment do not generally require special dosage adjustments, but patients with severe liver impairment may experience reduced efficacy. This medication generally does not interact significantly with other medications, but caution should be exercised as drug concentrations may change when used concurrently with certain medications. Women who are pregnant or may become pregnant should carefully consider the benefits and risks of using this medication, and breastfeeding women should consult a healthcare professional before taking it. Children under 18 years of age should generally not use this medication as its safety and efficacy have not been established. Elderly patients generally do not require dosage adjustments; however, dosage adjustments may be necessary in those with decreased kidney function. In cases of overdose, appropriate treatment is required, and blood dialysis may significantly lower the concentration of the active ingredient in this medication. This medication should be stored in a dry place below 30 degrees Celsius and kept out of reach of children, and it is safer not to transfer it to other containers.

• Headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is also recommended to store it in a cool, dry place below 30 degrees Celsius.

Appearance

White, round, film-coated tablet

Package unit

30 tablets/bottle